Anti-CD40 agonist antibodies: Preclinical and clinical experience
- 1 June 2007
- journal article
- review article
- Published by Elsevier in Update on Cancer Therapeutics
- Vol. 2 (2) , 61-65
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Giving blood: a new role for CD40 in tumorigenesisJournal of Experimental Medicine, 2006
- Triggering CD40 on endothelial cells contributes to tumor growthJournal of Experimental Medicine, 2006
- Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primatesBritish Journal of Pharmacology, 2006
- CTLA-4 Blockade: Autoimmunity As TreatmentJournal of Clinical Oncology, 2005
- Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFNJournal of Experimental Medicine, 2004
- Prospects for CD40-directed experimental therapy of human cancerCancer Gene Therapy, 2002
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- A novel function of CD40: induction of cell death in transformed cells.Journal of Experimental Medicine, 1996
- Molecular and biological characterization of a murine ligand for CD40Nature, 1992